Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Subcutaneous versus intravenous daratumumab in multiple myeloma - Authors' reply.
See All Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Subcutaneous versus intravenous daratumumab in multiple myeloma - Authors' reply.
Mateos MV, Usmani SZ. Subcutaneous versus intravenous daratumumab in multiple myeloma - Authors' reply. Lancet Haematol. 2020 08; 7(8):e559.
View in:
PubMed
subject areas
Administration, Intravenous
Antibodies, Monoclonal
Humans
Multiple Myeloma
authors with profiles
Saad Usmani MD